Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/23/21
End: 04/30/24
Due: 04/30/25
Phase: N/A
Priority: Normal
Start: 12/16/20
End: 08/06/21
Due: 08/06/22
Phase: N/A
Priority: Normal
Start: 03/06/19
End: 09/27/21
Due: 09/27/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo | NCT05070260 | Acticor Biotech | user2@example.com | None | 2021-09-23 | 2024-04-30 | 2025-04-30 | - | - | 2025-07-14 |
| Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 | NCT04659109 | Acticor Biotech | user2@example.com | None | 2020-12-16 | 2021-08-06 | 2022-08-06 | - | - | 2025-07-14 |
| Acute Ischemic Stroke Interventional Study | NCT03803007 | Acticor Biotech | user2@example.com | None | 2019-03-06 | 2021-09-27 | 2022-09-27 | - | - | 2025-07-14 |